News

  1. JHP Pharmaceuticals To Produce Lyophilized Biologic For International Late-Phase Clinical Trials 9/19/2012

    JHP Pharmaceuticals, a provider of global contract manufacturing services for sterile products has entered into an agreement with an undisclosed pharmaceutical company to produce supplies of a lyophilized biologic for international, late-phase clinical trials.

  2. INC Research Expands South Korean Presence With New Office 9/12/2012

    INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, recently announced the opening of a facility in South Korea to manage the growing demand for world-class clinical development programs. Located in the heart of Seoul's business district, the Company's South Korean team is primarily focused on study start-up and clinical operations activities around key therapeutic areas.

  3. Chiltern Welcomes Drs. Dieter Seitz-Tutter And Alexandra Adams 9/10/2012

    Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Drs. Dieter Seitz-Tutter and Alexandra Adams have joined Chiltern, bringing their extensive expertise in clinical research to serve our clients’ needs and to strengthen our Global Clinical Development service.

  4. Ampio Advances NCE001 Cancer Drug Into Preclinical Development Following Successful Recent Financing And The Granting Of Patents In USA, Canada, Europe And China 7/16/2012

    Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs (Ampion™, Optina™, Zertane™ & Zertane-ED™) announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

  5. Phase 3 MISSION Trial Of Nexavar (Sorafenib) In Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint Of Improving Overall Survival 5/22/2012

    Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.

  6. Inc Research Selects Transperfect's Trial Interactive Technology As Its Electronic Trial Master File (eTMF) Solution 5/14/2012

    TransPerfect, a leading provider of e-clinical technologies to the life sciences industry, recently announced that INC Research, a therapeutically focused clinical research organization (CRO), has selected Trial Interactive as its global electronic Trial Master File (eTMF) solution.

  7. AMRI Signs Exclusive Option To License Its Tubulin Inhibitor Program For Cancer 4/9/2012
    AMRI, a global contract healthcare services organization spanning the entire R&D continuum, announced recently that it has signed an exclusive option to enter a license agreement with Bessor Pharma, LLC a translational drug development company led by industry veteran Barry A. Berkowitz, Ph.D., for the development of ALB 109564(a), AMRI’s novel tubulin inhibitor compound in late Phase I testing for the treatment of cancer.
  8. Evado Opens Asian Support Centre 2/21/2012
    Evado Clinical Software has opened its Asian Help Desk Support Centre at the Singapore Clinical Research Institute (SCRI). The support centre will provide Evado's registry and research and commercial trial clients with bilingual support throughout the Asia-Pacific region.
  9. Harrison Clinical Research Selects BioClinica OnPoint CTMS 1/19/2012
    BioClinica, Inc., a global provider of clinical trial management solutions, announced recently a new agreement with Harrison Clinical Research (HCR), an international full-service contract research organization.
  10. PHT Corporation Achieves Industry Landmark With 500th ePRO Clinical Trial 1/13/2012
    PHT Corporation cemented its reputation as the dominant player and constant innovator in the Patient Reported Outcomes (PRO) and Electronic Patient Reported Outcomes (ePRO) industry with the announcement of its 500th clinical research trial.